CatalystFDA/Bio

BEAM THERAPEUTICS INC. (BEAM) DISCUSSES UPDATED PHASE 1/2 DATA FOR BEAM-302 IN ALPHA-1 ANTITRYPSIN DEFICIENCY TRANSCRIPT - SEEKINGALPHA

Updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency drives biotech relevance.

What changed

Updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency drives biotech relevance.

Why it matters

Updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency drives biotech relevance. — impact context not separately stored; see What changed.

Sources

seekingalpha